Abstract
Glutathione S-transferase Pi (GST P) has been reported to be a marker of dysplastic lesions. For this reason expression of GST P by intraduct breast carcinoma was evaluated by immunohistochemistry. Thirty-seven of 92 carcinomas (40%) were GST P positive. GST P staining did not correlate with histological variables, c-erbB-2 overexpression or with clinical outcome. The GST P status of recurrences did not correlate with that of the index lesion. There is little evidence that GST P is a useful marker of the potential of intraduct breast carcinoma to become invasive.
Highlights
For the purposes of analysis the three categories of Glutathione S-transferase Pi (GST P) staining were regarded as GST P positive, analyses comparing each individual category of GST P staining with all other categories did not yield any new correlations
It is apparent that cribriform DCIS was most often GST P positive (15 of 28 cases; 54%) and micropapillary DCIS was least often positive, these differences in expression were not statistically significant
GST P staining did not correlate significantly with nuclear grade [positive case for grade 1, 8/19 (42%); grade 2, 18/38 (47%); grade 3, 13/35 (37%)], or with the presence of necrosis [25/68 (37%) cases with necrosis GST P positive; 12/24 (50%) cases without necrosis GST P positive], or with the extent of breast affected by DCIS [single and multiquadrant DCIS were GST P positive in 21/ 52 (40%) cases and 5/10 (50%) cases respectively]
Summary
Ninety-two women with DCIS without previous breast carcinoma were studied. These patients represent part of a larger cohort of DCIS patients reported in detail elsewhere (Bellamy et al, 1993) and for whom material was available. Follow-up data were available for all patients. The tissue was formalin fixed and paraffin embedded and one block was selected from each case. Serial 4 iLm sections were cut, and one section was stained with haemotoxylineosin to confirm the presence of carcinoma in the study material. Blocks were selected from the recurrent carcinoma and, where present, from lymph node metastases
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
